Compare Ascendis Pharma A/S (ASND) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Franklin Resources, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Franklin Resources, Inc. trades at $33.57 (market cap $17.41B). The key difference: Ascendis Pharma A/S and Franklin Resources, Inc. are close in size by market cap, and Franklin Resources, Inc. pays a 3.94% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BEN | |
|---|---|---|
Market Cap | $17.74B | $17.41B |
Sector | Health | Financials |
52-Week High | $277.18 | $34.44 |
52-Week Low | $163.32 | $21.18 |
Enterprise Value | $18.11B | $29.23B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Franklin Resources (BEN) trades at $33.50, down 0.53% on the day, with a bullish technical outlook from moving averages and a consensus price target of $34.17. The company reported Q1 2026 EPS of $0.71, beating expectations of $0.55, and maintains strong profitability with an 80.72% gross margin. Recent news highlights its inclusion in dividend stock lists and a Zacks upgrade to Strong Buy on June 23, 2026, amid steady asset growth to $1.79 trillion AUM in June.
BEN presents a mixed outlook with solid earnings beats and dividend appeal offset by weak cash flow trends and modest growth. Upside is supported by analyst optimism and technical momentum, but risks include net cash outflows and competitive pressures in asset management. The stock's valuation at a P/E of 25.57 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
